|
EP2266552A2
(en)
|
2002-03-04 |
2010-12-29 |
Merck HDAC Research, LLC |
Methods of inducing terminal differentiation
|
|
WO2004003142A2
(en)
|
2002-06-28 |
2004-01-08 |
Xcyte Therapies, Inc. |
Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
WO2004103306A2
(en)
|
2003-05-19 |
2004-12-02 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
EP2644195A1
(en)
|
2003-05-19 |
2013-10-02 |
Irm Llc |
Immunosuppressant Compounds and Compositions
|
|
EP2039355A2
(en)
|
2003-06-25 |
2009-03-25 |
TopoTarget Germany AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
|
EP2149585A1
(en)
|
2003-11-04 |
2010-02-03 |
Novartis Vaccines and Diagnostics, Inc. |
Antagonist anti-CD40 monoclonal antibodies and methods for their use
|
|
EP1609494A1
(en)
|
2004-06-21 |
2005-12-28 |
Cordis Corporation |
Heparin barrier coating for controlled drug release
|
|
EP1759724A1
(en)
|
2005-08-31 |
2007-03-07 |
Cordis Corporation |
Antithrombotic coating for drug eluting medical devices
|
|
EP2174938A1
(en)
|
2006-10-12 |
2010-04-14 |
SuperGen, Inc. |
Quinoline derivatives for modulating DNA methylation
|
|
EP2489657A2
(en)
|
2006-10-28 |
2012-08-22 |
MethylGene Inc. |
Inhibitors of histone deacetylase
|
|
EP2343286A1
(en)
|
2006-10-28 |
2011-07-13 |
Methylgene, Inc. |
Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase
|
|
WO2008055068A2
(en)
|
2006-10-28 |
2008-05-08 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
|
WO2008060932A2
(en)
|
2006-11-08 |
2008-05-22 |
Aldagen, Inc. |
Methods for improved engraftment following stem cell transplantation
|
|
WO2008059052A1
(en)
|
2006-11-17 |
2008-05-22 |
Innate Pharma |
Improved methods of using phosphoantigen for the treatment of cancer
|
|
EP1974758A2
(en)
|
2007-03-28 |
2008-10-01 |
Cordis Corporation |
Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, AAA and stroke
|
|
EP2213727A1
(en)
|
2007-06-15 |
2010-08-04 |
Ipierian, Inc. |
Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue
|
|
WO2009117439A2
(en)
|
2008-03-17 |
2009-09-24 |
The Scripps Research Institute |
Combined chemical and genetic approaches for generation of induced pluripotent stem cells
|
|
EP2108390A2
(en)
|
2008-03-31 |
2009-10-14 |
Cordis Corporation |
Device for local and/or regional delivery employing liquid formulations of therapeutic agents
|
|
WO2010071794A1
(en)
|
2008-12-18 |
2010-06-24 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
|
WO2010089327A2
(en)
|
2009-02-04 |
2010-08-12 |
Janssen Pharmaceutica Nv |
Indole derivatives as anticancer agents
|
|
WO2010120942A2
(en)
|
2009-04-14 |
2010-10-21 |
The Regents Of The University Of California |
Histone modification patterns for clinical diagnosis and prognosis of cancer
|
|
WO2011015652A1
(en)
|
2009-08-07 |
2011-02-10 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators
|
|
WO2011018454A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
WO2011054828A1
(en)
|
2009-11-04 |
2011-05-12 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
|
WO2011070030A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
WO2011076786A1
(en)
|
2009-12-22 |
2011-06-30 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
WO2011130728A1
(en)
|
2010-04-17 |
2011-10-20 |
Bayer Healthcare Llc |
Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
|
|
WO2011135459A2
(en)
|
2010-04-29 |
2011-11-03 |
Medical Prognosis Institute A/S |
Methods and devices for predicting treatment efficacy
|
|
WO2011159797A2
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
A compendium of ready-built stem cell models for interrogation of biological response
|
|
WO2012012404A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
WO2012061082A2
(en)
|
2010-10-25 |
2012-05-10 |
Marrone Bio Innovations, Inc. |
Chromobacterium bioactive compositions and metabolites
|
|
EP3660029A1
(en)
|
2010-12-09 |
2020-06-03 |
The Trustees of The University of Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
EP3868747A1
(en)
|
2011-04-21 |
2021-08-25 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
|
WO2012168884A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
EP3795145A2
(en)
|
2011-08-17 |
2021-03-24 |
Dennis M. Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
|
|
EP3656848A1
(en)
|
2011-09-30 |
2020-05-27 |
Bluebird Bio, Inc. |
Compounds for improved viral transduction
|
|
EP3736265A1
(en)
|
2011-10-20 |
2020-11-11 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
WO2013080141A1
(en)
|
2011-11-29 |
2013-06-06 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
WO2013096049A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
WO2013096051A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
EP3272754A1
(en)
|
2012-01-26 |
2018-01-24 |
Novartis AG |
Imidazopyrrolidinone compounds
|
|
WO2013126733A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of University Of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
WO2013138343A1
(en)
|
2012-03-16 |
2013-09-19 |
The Johns Hopkins University |
Controlled release formulations for the delivery of hif-1 inhibitors
|
|
WO2013171641A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
WO2013171640A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
WO2013175417A1
(en)
|
2012-05-24 |
2013-11-28 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
|
WO2013176915A1
(en)
|
2012-05-25 |
2013-11-28 |
Roman Galetto |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
EP4541818A2
(en)
|
2012-05-25 |
2025-04-23 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
EP3279315A2
(en)
|
2012-05-25 |
2018-02-07 |
Cellectis |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
|
EP3473707A1
(en)
|
2012-05-25 |
2019-04-24 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
EP4461308A2
(en)
|
2012-07-13 |
2024-11-13 |
The Trustees of The University of Pennsylvania |
Toxicity management for anti-tumor activity of cars
|
|
EP3730512A1
(en)
|
2012-07-13 |
2020-10-28 |
The Trustees of the University of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
|
WO2014022116A2
(en)
|
2012-07-28 |
2014-02-06 |
Calitor Sciences, Llc |
Substituted pyrazolone compounds and methods of use
|
|
WO2014039523A1
(en)
|
2012-09-04 |
2014-03-13 |
Cellectis |
Multi-chain chimeric antigen receptor and uses thereof
|
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
|
WO2014184741A1
(en)
|
2013-05-13 |
2014-11-20 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotheraphy
|
|
EP3470536A1
(en)
|
2013-10-01 |
2019-04-17 |
The J. David Gladstone Institutes |
Compositions, systems and methods for gene expression noise drug screening and uses thereof
|
|
WO2015051035A1
(en)
|
2013-10-01 |
2015-04-09 |
The J. David Gladstone Institutes |
Compositions, systems and methods for gene expression noise drug screening and uses thereof
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
WO2015121454A1
(en)
|
2014-02-14 |
2015-08-20 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
EP3834827A1
(en)
|
2014-02-20 |
2021-06-16 |
Ignyta, Inc. |
N-[5-(3,5-difluorobenzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2h-pyran-4-ylamino) benzamide for treating patients with ros1,ntrk1, ntrk2 and ntrk3 mutant cancer cells
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
EP4368705A2
(en)
|
2014-03-11 |
2024-05-15 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
|
EP3811970A1
(en)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP3848034A1
(en)
|
2014-03-26 |
2021-07-14 |
Astex Therapeutics Limited |
Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
|
|
EP3888674A1
(en)
|
2014-04-07 |
2021-10-06 |
Novartis AG |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
WO2015168613A2
(en)
|
2014-05-02 |
2015-11-05 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
|
EP3524616A1
(en)
|
2014-05-02 |
2019-08-14 |
Cellectis |
Cs1 specific multi-chain chimeric antigen receptor
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
|
EP3967709A1
(en)
|
2014-09-17 |
2022-03-16 |
Novartis AG |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
EP3662903A2
(en)
|
2014-10-03 |
2020-06-10 |
Novartis AG |
Combination therapies
|
|
EP4219725A2
(en)
|
2014-10-31 |
2023-08-02 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
WO2016069993A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding t cells
|
|
WO2016100932A1
(en)
|
2014-12-19 |
2016-06-23 |
Immusoft Corporation |
B cells for in vivo delivery of therapeutic agents
|
|
WO2016120219A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
EP4223873A2
(en)
|
2015-01-31 |
2023-08-09 |
The Trustees of the University of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
|
WO2016135557A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
WO2016138491A1
(en)
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
EP3549612A1
(en)
|
2015-03-02 |
2019-10-09 |
Innovative Cellular Therapeutics Co., Ltd. |
Reducing immune tolerance induced by pd-l1
|
|
WO2016142532A1
(en)
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
WO2016151499A1
(en)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
|
WO2016166630A1
(en)
|
2015-04-13 |
2016-10-20 |
Pfizer Inc. |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
EP4234685A2
(en)
|
2015-04-17 |
2023-08-30 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US11028142B2
(en)
|
2015-05-18 |
2021-06-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11965012B2
(en)
|
2015-05-18 |
2024-04-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US10442849B2
(en)
|
2015-05-18 |
2019-10-15 |
Tcr2 Therabeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US10358474B2
(en)
|
2015-05-18 |
2019-07-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US10358473B2
(en)
|
2015-05-18 |
2019-07-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US10954311B2
(en)
|
2015-05-21 |
2021-03-23 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
US12084518B2
(en)
|
2015-05-21 |
2024-09-10 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
EP3845557A1
(en)
|
2015-06-12 |
2021-07-07 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
WO2016201394A1
(en)
|
2015-06-12 |
2016-12-15 |
Miltenyi Biotec Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
EP4286511A2
(en)
|
2015-06-12 |
2023-12-06 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
EP4339287A2
(en)
|
2015-07-31 |
2024-03-20 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
WO2017025323A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
EP4063397A1
(en)
|
2015-08-11 |
2022-09-28 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
|
|
EP3896091A1
(en)
|
2015-08-11 |
2021-10-20 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
EP4424376A2
(en)
|
2015-08-11 |
2024-09-04 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
WO2017067447A1
(en)
|
2015-10-19 |
2017-04-27 |
Sunshine Lake Pharma Co., Ltd. |
A salt of egfr inhibitor, crystalline form and uses thereof
|
|
EP4458957A2
(en)
|
2015-11-23 |
2024-11-06 |
Novartis AG |
Optimized lentiviral transfer vectors and uses thereof
|
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
|
WO2017112741A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
EP4477748A2
(en)
|
2015-12-28 |
2024-12-18 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP4219689A2
(en)
|
2015-12-30 |
2023-08-02 |
Novartis AG |
Immune effector cell therapies with enhanced efficacy
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
EP3884939A1
(en)
|
2016-03-09 |
2021-09-29 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
EP4234552A2
(en)
|
2016-03-09 |
2023-08-30 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
EP3988111A1
(en)
|
2016-04-01 |
2022-04-27 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
WO2017178586A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
|
WO2017182608A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US11453716B2
(en)
|
2016-05-20 |
2022-09-27 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
WO2017214333A1
(en)
|
2016-06-08 |
2017-12-14 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
US12297274B2
(en)
|
2016-06-10 |
2025-05-13 |
Umc Utrecht Holding B.V. |
Method of cell therapy
|
|
WO2017212072A1
(en)
|
2016-06-10 |
2017-12-14 |
Umc Utrecht Holding B.V. |
Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
|
|
EP3808748A1
(en)
|
2016-06-21 |
2021-04-21 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
|
WO2017223239A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
EP3269740A1
(en)
|
2016-07-13 |
2018-01-17 |
Mabimmune Diagnostics AG |
Novel anti-fibroblast activation protein (fap) binding agents and uses thereof
|
|
EP4606890A2
(en)
|
2016-07-13 |
2025-08-27 |
President and Fellows of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
WO2018014122A1
(en)
|
2016-07-18 |
2018-01-25 |
Helix Biopharma Corp. |
Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
|
|
WO2018026819A2
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
US11242376B2
(en)
|
2016-08-02 |
2022-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
WO2021102337A1
(en)
|
2016-09-02 |
2021-05-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
WO2020061194A2
(en)
|
2016-09-02 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
EP4282969A2
(en)
|
2016-09-02 |
2023-11-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
US11085021B2
(en)
|
2016-10-07 |
2021-08-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
EP3848392A1
(en)
|
2016-10-07 |
2021-07-14 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US10208285B2
(en)
|
2016-10-07 |
2019-02-19 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US11377638B2
(en)
|
2016-10-07 |
2022-07-05 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP3848370A2
(en)
|
2016-10-14 |
2021-07-14 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2018098365A2
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US10844134B2
(en)
|
2016-11-23 |
2020-11-24 |
Harpoon Therapeutics, Inc. |
PSMA targeting trispecific proteins and methods of use
|
|
US10849973B2
(en)
|
2016-11-23 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
|
WO2018119298A1
(en)
|
2016-12-21 |
2018-06-28 |
TCR2 Therapeutics Inc. |
Engineered t cells for the treatment of cancer
|
|
EP4219486A1
(en)
|
2017-01-19 |
2023-08-02 |
Temple University of the Commonwealth System of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
|
WO2018157072A1
(en)
|
2017-02-27 |
2018-08-30 |
Life Technologies Corporation |
Expansion of populations of t cells by the use of modified serum free media
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
EP4338802A2
(en)
|
2017-03-08 |
2024-03-20 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EP4414380A2
(en)
|
2017-03-31 |
2024-08-14 |
Cellectis SA |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
|
WO2018178378A1
(en)
|
2017-03-31 |
2018-10-04 |
Cellectis Sa |
New universal chimeric antigen receptor t cells specific for cd22
|
|
WO2018193394A1
(en)
|
2017-04-19 |
2018-10-25 |
Allogene Therapeutics, Inc. |
Improved t cell compositions and methods
|
|
US11607453B2
(en)
|
2017-05-12 |
2023-03-21 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2019069125A1
(en)
|
2017-10-06 |
2019-04-11 |
Oslo Universitetssykehus Hf |
Chimeric antigen receptors
|
|
US11136403B2
(en)
|
2017-10-13 |
2021-10-05 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
US11976125B2
(en)
|
2017-10-13 |
2024-05-07 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
|
US10927180B2
(en)
|
2017-10-13 |
2021-02-23 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
|
US12371504B2
(en)
|
2017-10-13 |
2025-07-29 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
WO2019108900A1
(en)
|
2017-11-30 |
2019-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019110734A1
(en)
|
2017-12-08 |
2019-06-13 |
Janssen Pharmaceutica Nv |
Novel spirobicyclic analogues
|
|
WO2019129851A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Method for improving production of car t cells
|
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
|
WO2019140100A1
(en)
|
2018-01-11 |
2019-07-18 |
Innovative Cellular Therapeutics Inc. |
Modified cell expansion and uses thereof
|
|
EP3586852A1
(en)
|
2018-01-11 |
2020-01-01 |
Innovative Cellular Therapeutics Inc. |
Modified cell expansion and uses thereof
|
|
WO2019143961A2
(en)
|
2018-01-19 |
2019-07-25 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors
|
|
WO2019149743A1
(en)
|
2018-01-30 |
2019-08-08 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
WO2019150196A1
(en)
|
2018-02-05 |
2019-08-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019169001A1
(en)
|
2018-02-27 |
2019-09-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
WO2019178613A1
(en)
|
2018-03-16 |
2019-09-19 |
Immusoft Corporation |
B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
|
|
WO2019209757A1
(en)
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
WO2019209759A1
(en)
|
2018-04-24 |
2019-10-31 |
Merck Patent Gmbh |
Antiproliferation compounds and uses thereof
|
|
WO2019213434A1
(en)
|
2018-05-02 |
2019-11-07 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
|
|
WO2019217512A1
(en)
|
2018-05-08 |
2019-11-14 |
Life Technologies Corporation |
Compositions and methods for culturing and expanding cells
|
|
US12415860B2
(en)
|
2018-05-14 |
2025-09-16 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
WO2019241426A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
EP4302827A2
(en)
|
2018-06-15 |
2024-01-10 |
JANSSEN Pharmaceutica NV |
Rapamycin analogs and uses thereof
|
|
EP4464715A2
(en)
|
2018-06-22 |
2024-11-20 |
BicycleTx Limited |
Bicyclic peptide ligands specific for nectin-4
|
|
EP4588934A2
(en)
|
2018-06-22 |
2025-07-23 |
BicycleTX Limited |
Bicyclic peptide ligands specific for nectin-4
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020012337A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
|
|
WO2020018825A1
(en)
|
2018-07-19 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with bcma specificity and uses thereof
|
|
EP4324851A2
(en)
|
2018-07-19 |
2024-02-21 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with bcma specificity and uses thereof
|
|
WO2020047306A1
(en)
|
2018-08-30 |
2020-03-05 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cells for treating solid tumor
|
|
WO2020047501A1
(en)
|
2018-08-30 |
2020-03-05 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2020047452A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US11807692B2
(en)
|
2018-09-25 |
2023-11-07 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
WO2020088631A1
(en)
|
2018-11-01 |
2020-05-07 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
EP4578507A2
(en)
|
2018-11-01 |
2025-07-02 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
WO2020157704A1
(en)
|
2019-01-30 |
2020-08-06 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer based on molecular subtypes
|
|
WO2020176397A1
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
WO2020239478A1
(en)
|
2019-05-28 |
2020-12-03 |
Pharma Mar, S.A. |
Trabectedin for treating sarcomas based on genomic markers
|
|
WO2021016608A1
(en)
|
2019-07-25 |
2021-01-28 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
WO2021032779A1
(en)
|
2019-08-19 |
2021-02-25 |
Universität Basel |
Cell therapy methods
|
|
WO2021050601A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
WO2021108613A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
WO2021130250A1
(en)
|
2019-12-23 |
2021-07-01 |
Cellectis |
New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
|
|
WO2021146604A1
(en)
|
2020-01-16 |
2021-07-22 |
Allogene Therapeutics, Inc. |
Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors
|
|
US11180563B2
(en)
|
2020-02-21 |
2021-11-23 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2021178488A1
(en)
|
2020-03-03 |
2021-09-10 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
|
EP4617364A2
(en)
|
2020-06-04 |
2025-09-17 |
Carisma Therapeutics Inc. |
Novel constructs for chimeric antigen receptors
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2022016112A1
(en)
|
2020-07-17 |
2022-01-20 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
WO2022140388A1
(en)
|
2020-12-21 |
2022-06-30 |
Allogene Therapeutics, Inc. |
Protease-activating cd45-gate car
|
|
WO2022187663A1
(en)
|
2021-03-04 |
2022-09-09 |
Allogene Therapeutics, Inc. |
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
WO2022235662A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
|
WO2022235832A1
(en)
|
2021-05-06 |
2022-11-10 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
|
WO2022261018A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
WO2023034571A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
|
WO2023114918A1
(en)
|
2021-12-16 |
2023-06-22 |
Ludwig Institute For Cancer Research Ltd |
Antisense transfer vectors and methods of use thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023192895A1
(en)
|
2022-03-29 |
2023-10-05 |
Allogene Therapeutics Inc. |
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
WO2025133340A1
(en)
|
2023-12-21 |
2025-06-26 |
Ludwig Institute For Cancer Research Ltd |
Heterodimeric proteins comprising dimerization motifs and methods of using
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|